CD274 and non-small cell lung carcinoma: 2023;24:1002–1017.⚬ This phase 3 study is of major importance, demonstrating a significant increase in survival of patients with metastatic NSCLC that had progressed on platinum-based therapy treated with TTFields therapy concomitant with PD-(L)1 inhibitors or docetaxel.